Avacta Life Sciences Limited
  • About
  • Therapeutics
  • Diagnostics
  • Investors
  • News
  • Careers
  • Contact
  • About
    • About Avacta
    • People
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • Affimer®
    • preCISIONTM
    • Pipeline
    • Partnering
    • Clinical trials
    • News
  • Diagnostics
    • Diagnostics
    • Products
    • Affimer®
    • Key benefits
    • Partnering
    • Resources
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key information
    • Corporate Governance
    • Documents & Presentations
    • Share price
    • RNS News
  • News
  • Careers
    • CEO Welcome
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
  • About
    • About Avacta
    • People
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • Affimer®
    • preCISIONTM
    • Pipeline
    • Partnering
    • Clinical trials
    • News
  • Diagnostics
    • Diagnostics
    • Products
    • Affimer®
    • Key benefits
    • Partnering
    • Resources
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key information
    • Corporate Governance
    • Documents & Presentations
    • Share price
    • RNS News
  • News
  • Careers
    • CEO Welcome
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
Home News
filter by: view all | Blogs | Diagnostics | Investors | Therapeutics

News

31 May 2022

Posting of Annual Report and Notice of AGM

Investors
16 May 2022

AffyXell expands its strategic partnership with GenScript ProBio

Investors | Therapeutics
11 May 2022

Avacta establishes new Therapeutics headquarters at Scale Space, Imperial College White City Campus

Investors | Therapeutics
13 Apr 2022

AffyXell joint venture milestone and increased equity stake

Investors | Therapeutics
12 Apr 2022

Poster presented at the American Association for Cancer Research Annual Meeting available to download

Investors | Therapeutics
08 Apr 2022

AffyXell partners with Biocytogen and the Korea Non-clinical Technology Support Center

Investors | Therapeutics
06 Apr 2022

Preliminary Results for the year ending 31 December 2021

Investors
30 Mar 2022

Notice of Results and Investor Presentation

Investors
29 Mar 2022

Avacta to present pre-clinical data on AVA6000 at the American Association for Cancer Research Annual Meeting

Investors | Therapeutics
21 Mar 2022

Directorate Change

Investors | Therapeutics

Posts navigation

Older posts
Newer posts
Avacta Life Sciences Limited
  • Terms of Use
  • Terms & Conditions
  • Privacy Policy
  • Intellectual Property
  • Returns & cancellations policy
  • Corporate Responsibility
  • Contact Us

Avacta Diagnostics

Unit 20, Ash Way
Thorp Arch Estate
Wetherby
LS23 7FA
+44 (0)1904 21 7070

virtual tour
email

Avacta Therapeutics

Scale Space,  White City
Imperial College Campus
58 Wood Lane
London
W12 7RZ

+44 (0)20 3871 9700

Investor Enquiries

FTI Consulting
200 Aldersgate
Aldersgate Street
London
EC1A 4HD

Email

Twitter | Linkedin

©2023 Avacta Life Sciences Limited. Registered company no. 06605196.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok